ESPERION THERAPEUTICS INC (ESPR) Fundamental Analysis & Valuation

NASDAQ:ESPR • US29664W1053

Current stock price

2.22 USD
+0.05 (+2.3%)
At close:
2.24 USD
+0.02 (+0.9%)
After Hours:

This ESPR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ESPR Profitability Analysis

1.1 Basic Checks

  • ESPR had negative earnings in the past year.
  • ESPR had a negative operating cash flow in the past year.
  • ESPR had negative earnings in each of the past 5 years.
  • In the past 5 years ESPR always reported negative operating cash flow.
ESPR Yearly Net Income VS EBIT VS OCF VS FCFESPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • ESPR has a Return On Assets of -4.87%. This is in the better half of the industry: ESPR outperforms 73.30% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 28.84%, ESPR belongs to the top of the industry, outperforming 97.91% of the companies in the same industry.
Industry RankSector Rank
ROA -4.87%
ROE N/A
ROIC 28.84%
ROA(3y)-40.53%
ROA(5y)-57.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESPR Yearly ROA, ROE, ROICESPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400

1.3 Margins

  • Looking at the Operating Margin, with a value of 14.95%, ESPR belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
  • ESPR has a better Gross Margin (67.95%) than 75.92% of its industry peers.
  • In the last couple of years the Gross Margin of ESPR has declined.
Industry RankSector Rank
OM 14.95%
PM (TTM) N/A
GM 67.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.89%
GM growth 5Y-7.25%
ESPR Yearly Profit, Operating, Gross MarginsESPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ESPR Health Analysis

2.1 Basic Checks

  • ESPR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • ESPR has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ESPR has been increased compared to 5 years ago.
  • Compared to 1 year ago, ESPR has an improved debt to assets ratio.
ESPR Yearly Shares OutstandingESPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ESPR Yearly Total Debt VS Total AssetsESPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • ESPR has an Altman-Z score of -2.73. This is a bad value and indicates that ESPR is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ESPR (-2.73) is worse than 60.73% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.73
ROIC/WACC3.7
WACC7.8%
ESPR Yearly LT Debt VS Equity VS FCFESPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M

2.3 Liquidity

  • A Current Ratio of 1.54 indicates that ESPR should not have too much problems paying its short term obligations.
  • The Current ratio of ESPR (1.54) is worse than 74.35% of its industry peers.
  • A Quick Ratio of 1.19 indicates that ESPR should not have too much problems paying its short term obligations.
  • The Quick ratio of ESPR (1.19) is worse than 75.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.19
ESPR Yearly Current Assets VS Current LiabilitesESPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ESPR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 32.00% over the past year.
  • The Revenue has grown by 21.31% in the past year. This is a very strong growth!
  • Measured over the past years, ESPR shows a quite strong growth in Revenue. The Revenue has been growing by 12.12% on average per year.
EPS 1Y (TTM)32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)21.31%
Revenue growth 3Y74.78%
Revenue growth 5Y12.12%
Sales Q2Q%143.73%

3.2 Future

  • The Earnings Per Share is expected to grow by 70.88% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ESPR will show a very strong growth in Revenue. The Revenue will grow by 23.97% on average per year.
EPS Next Y129.4%
EPS Next 2Y95.34%
EPS Next 3Y74.17%
EPS Next 5Y70.88%
Revenue Next Year-2.01%
Revenue Next 2Y-1.83%
Revenue Next 3Y10.55%
Revenue Next 5Y23.97%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ESPR Yearly Revenue VS EstimatesESPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ESPR Yearly EPS VS EstimatesESPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

4

4. ESPR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ESPR. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 44.42, ESPR can be considered very expensive at the moment.
  • ESPR's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ESPR is cheaper than 73.30% of the companies in the same industry.
  • ESPR's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 37.96.
Industry RankSector Rank
PE N/A
Fwd PE 44.42
ESPR Price Earnings VS Forward Price EarningsESPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ESPR is valued cheaply inside the industry as 82.20% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.48
ESPR Per share dataESPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ESPR's earnings are expected to grow with 74.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y95.34%
EPS Next 3Y74.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ESPR Dividend Analysis

5.1 Amount

  • No dividends for ESPR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ESPR Fundamentals: All Metrics, Ratios and Statistics

ESPERION THERAPEUTICS INC

NASDAQ:ESPR (4/13/2026, 7:18:46 PM)

After market: 2.24 +0.02 (+0.9%)

2.22

+0.05 (+2.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-10
Earnings (Next)05-04
Inst Owners57.6%
Inst Owner Change0.02%
Ins Owners0.93%
Ins Owner Change10.25%
Market Cap570.12M
Revenue(TTM)403.13M
Net Income(TTM)-22.68M
Analysts78.57
Price Target6.86 (209.01%)
Short Float %13.68%
Short Ratio7.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-97.09%
Min EPS beat(2)-183.71%
Max EPS beat(2)-10.46%
EPS beat(4)1
Avg EPS beat(4)-35.16%
Min EPS beat(4)-183.71%
Max EPS beat(4)86.52%
EPS beat(8)4
Avg EPS beat(8)55.06%
EPS beat(12)6
Avg EPS beat(12)38.54%
EPS beat(16)9
Avg EPS beat(16)30.59%
Revenue beat(2)1
Avg Revenue beat(2)2.32%
Min Revenue beat(2)-5.37%
Max Revenue beat(2)10.02%
Revenue beat(4)3
Avg Revenue beat(4)12.5%
Min Revenue beat(4)-5.37%
Max Revenue beat(4)28.11%
Revenue beat(8)6
Avg Revenue beat(8)21.55%
Revenue beat(12)10
Avg Revenue beat(12)17.18%
Revenue beat(16)11
Avg Revenue beat(16)12.9%
PT rev (1m)-1.51%
PT rev (3m)3.98%
EPS NQ rev (1m)-1725.33%
EPS NQ rev (3m)-476.42%
EPS NY rev (1m)-64.97%
EPS NY rev (3m)26.84%
Revenue NQ rev (1m)-8.81%
Revenue NQ rev (3m)-13.92%
Revenue NY rev (1m)0.83%
Revenue NY rev (3m)4.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 44.42
P/S 1.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 15.48
EPS(TTM)-0.17
EYN/A
EPS(NY)0.05
Fwd EY2.25%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS1.57
BVpS-1.18
TBVpS-1.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.87%
ROE N/A
ROCE 36.51%
ROIC 28.84%
ROICexc N/A
ROICexgc N/A
OM 14.95%
PM (TTM) N/A
GM 67.95%
FCFM N/A
ROA(3y)-40.53%
ROA(5y)-57.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.89%
GM growth 5Y-7.25%
F-Score4
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 7.58
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage 3.71
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.19
Altman-Z -2.73
F-Score4
WACC7.8%
ROIC/WACC3.7
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y129.4%
EPS Next 2Y95.34%
EPS Next 3Y74.17%
EPS Next 5Y70.88%
Revenue 1Y (TTM)21.31%
Revenue growth 3Y74.78%
Revenue growth 5Y12.12%
Sales Q2Q%143.73%
Revenue Next Year-2.01%
Revenue Next 2Y-1.83%
Revenue Next 3Y10.55%
Revenue Next 5Y23.97%
EBIT growth 1Y10.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.15%
EBIT Next 3Y3%
EBIT Next 5Y28.54%
FCF growth 1Y45.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.65%
OCF growth 3YN/A
OCF growth 5YN/A

ESPERION THERAPEUTICS INC / ESPR Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ESPERION THERAPEUTICS INC (ESPR) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ESPR.


Can you provide the valuation status for ESPERION THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to ESPERION THERAPEUTICS INC (ESPR). This can be considered as Fairly Valued.


How profitable is ESPERION THERAPEUTICS INC (ESPR) stock?

ESPERION THERAPEUTICS INC (ESPR) has a profitability rating of 3 / 10.


What is the earnings growth outlook for ESPERION THERAPEUTICS INC?

The Earnings per Share (EPS) of ESPERION THERAPEUTICS INC (ESPR) is expected to grow by 129.4% in the next year.